SLC5A2 and heart failure: Although previous evidence synthesis confirmed the diminishing relative effects of SGLT2 inhibitors in patients with heart failure over time (Zou et al., 2024; Zou et al., 2022), the results of this microsimulation study using real-world patients in China indicate an enhanced cost-effectiveness over time.